According to SPER Market Research, the multiplex assays market estimated to reach USD 5.6 billion by 2030 with a CAGR of 7.2%.
Rising prevalence of chronic diseases, neurodegenerative disorders and cancers across the globe is a key driver for the growth of multiplex assays market.
A multiplex assay is a immunoassay which utilizes magnetic beads to measures multiple analytes such as proteins & other biomolecules in a single experiment. Multiplex assay provides information on various analytes for the biological processes. This helps the clinicians to identify a disease and stage the progression.
The multiplex assays are better than singleplex assay in terms of accuracy of detection and time taken for identification. Multiplex assay can detect the biomolecules at a lower reagent and analyte concentration.
The consumables market is the largest product & service segment by share in this market. The large share of this segment is mainly ascribed by rising research and development and increasing adoption of assays and reagents. North America dominated the market by regional segmentation owing to rising prevalence of chronic diseases, cancers and neurodegenerative disorders, high investment in R&D, presence of strong pharmaceutical and biotechnology industry and rising adoption of technologically advanced products.
The global multiplex assays market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as Abcam plc, Agilent Technologies, Inc., Antigenix America, Inc., AYOXXA Biosystems GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Boster Biological Technology, Cayman Chemical Company, DiaSorin S.p.A., Enzo Life Sciences, Inc., Illumina, Inc, Luminex Corporation, Merck KGaA, Meso Scale Diagnostics Olink, PerkinElmer, Inc., Promega Corporation, Qiagen N.V., Quanterix, Randox Laboratories, Seegene, Shimadzu Biotech, Siemens Healthineers, Thermo Fisher Scientific Inc.
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for product & service segment-Consumables, Instruments, Software & Service; for type segment- Protein Multiplex Assays (Planar Protein Assays, Bead-Based Protein Assays, Other Protein Assays), Nucleic Acid Multiplex Assays (Planar Nucleic Acid Assays, Bead-Based Nucleic Acid Assays, Other Nucleic Acid Assays), Cell-Based Multiplex Assays; for technology segment- Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time PCR, Other Technologies; for application segment- Research & Development (Drug Discovery & Development, Biomarker Discovery & Validation), Clinical Diagnostics (Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Nervous System Disorders, Metabolism & Endocrinology Disorders, Other Diseases; for end user segment- Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Reference Laboratories, Other End Users. This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World.
This study also encompasses various drivers and restraining factors for this market for the forecast period. Various growth opportunities are also discussed in the report.